Coya Therapeutics, Inc. (NASDAQ:COYA) announced the expansion of its investigational pipeline and advancement of COYA 303 for ...

Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), used to treat diabetes and for weight loss, may be linked with a reduced risk of substance use and neurocognitive disorders, a US study in people ...

More than one-third of websites selling their own versions implied the products were the same as the FDA-approved drugs.

An observational study has uncovered a possible link between taking GLP-1s and increased risk of kidney, pancreas and gut ...

Research has found that GLP-1 receptors, found in medications like Wegovy and Monjaro, may offer health benefits beyond the ...

A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like Ozempic and Wegovy, provide significant neurological and behavioral health ...

The use of weight-loss jabs may be associated with wider health benefits including lower risk of stroke and dementia, a study ...

Researchers have found links to multiple new benefits – and new side effects – in a study of weight-loss drugs such as ...

Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed.